Empagliflozin
- Generic Name
- Empagliflozin
- Brand Names
- Glyxambi, Jardiance, Synjardy, Trijardy
- Drug Type
- Small Molecule
- Chemical Formula
- C23H27ClO7
- CAS Number
- 864070-44-0
- Unique Ingredient Identifier
- HDC1R2M35U
- Background
Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies, for the management of type 2 diabetes mellitus.
...
- Indication
Empagliflozin is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes, either alone or in combination with metformin or linagliptin. It is also indicated to reduce the risk of cardiovascular death in adult patients with both type 2 diabetes mellitus and established cardiovascular disease, either alone or a...
- Associated Conditions
- Cardiovascular Mortality, Chronic Kidney Disease (CKD), End Stage Renal Disease (ESRD), Hospitalizations, Symptomatic Congestive Heart Failure, Type 2 Diabetes Mellitus, Decreased estimated glomerular filtration rate
- Associated Therapies
- Monotherapy
A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease
- Conditions
- Interventions
- First Posted Date
- 2018-04-10
- Last Posted Date
- 2018-08-27
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 714582
- Registration Number
- NCT03492580
- Locations
- 🇺🇸
Janssen Investigative Site, Titusville, New Jersey, United States
Are the "Cardiac Benefits" of Empagliflozin Independent of Its Hypoglycemic Activity? (ATRU-4).
- First Posted Date
- 2018-04-02
- Last Posted Date
- 2021-03-25
- Lead Sponsor
- Icahn School of Medicine at Mount Sinai
- Target Recruit Count
- 84
- Registration Number
- NCT03485222
- Locations
- 🇺🇸
Mount Sinai Heart - Icahn School of Medicine at Mount Sinai, New York, New York, United States
Empa PASS on Urinary Tract Malignancies
- First Posted Date
- 2018-03-13
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 98000
- Registration Number
- NCT03464045
- Locations
- 🇬🇧
United Kingdom Clinical Practice Research Datalink (CPRD), London, United Kingdom
🇸🇪The Swedish prescribed drug register, Stockholm, Sweden
🇫🇮The National Register Data, Helsinki, Finland
Comparison of Pharmacodynamic Effects of Sotagliflozin and Empagliflozin in T2DM Patients With Mild to Moderate Hypertension
- Conditions
- Interventions
- First Posted Date
- 2018-03-12
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 41
- Registration Number
- NCT03462069
- Locations
- 🇩🇪
Investigational Site Number 2760001, Berlin, Germany
This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Preserved Ejection Fraction (HFpEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure Symptoms.
- First Posted Date
- 2018-02-28
- Last Posted Date
- 2020-12-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 315
- Registration Number
- NCT03448406
- Locations
- 🇺🇸
Cox Medical Center South, Springfield, Missouri, United States
🇺🇸Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States
🇺🇸Acacia Medical Research Institute,LLC, Sugar Land, Texas, United States
This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure Symptoms
- First Posted Date
- 2018-02-28
- Last Posted Date
- 2020-11-27
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 312
- Registration Number
- NCT03448419
- Locations
- 🇺🇸
University Of Mississippi Medical Center, Jackson, Mississippi, United States
🇺🇸Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States
🇺🇸The Center for Clinical Trials, Inc., Saraland, Alabama, United States
Diabetes Study of Linagliptin and Empagliflozin in Children and Adolescents (DINAMO)TM
- Conditions
- Interventions
- First Posted Date
- 2018-02-12
- Last Posted Date
- 2024-02-23
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 175
- Registration Number
- NCT03429543
- Locations
- 🇺🇸
Children's Center for Advanced Pediatrics, Atlanta, Georgia, United States
🇺🇸Atlanta Center, Atlanta, Georgia, United States
🇺🇸Stanford University Medical Center, Palo Alto, California, United States
Comparative Effectiveness of Empagliflozin in the US
- Conditions
- Interventions
- First Posted Date
- 2017-12-06
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 230000
- Registration Number
- NCT03363464
- Locations
- 🇺🇸
Bringham Women Hospital, Boston, Massachusetts, United States
Efficacy and Safety of Sotagliflozin Versus Placebo and Empagliflozin in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking a DPP4 Inhibitor Alone or With Metformin
- Conditions
- Interventions
- First Posted Date
- 2017-11-22
- Last Posted Date
- 2021-05-11
- Lead Sponsor
- Lexicon Pharmaceuticals
- Target Recruit Count
- 770
- Registration Number
- NCT03351478
- Locations
- 🇺🇸
Investigational Site Number 8408010, Knoxville, Tennessee, United States
🇺🇸Investigational Site Number 8408038, Knoxville, Tennessee, United States
🇧🇬Investigational Site Number 1008005, Ruse, Bulgaria
A Study That Looks at the Function of the Heart in Patients With Heart Failure Who Take Empagliflozin
- First Posted Date
- 2017-11-06
- Last Posted Date
- 2021-06-18
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 72
- Registration Number
- NCT03332212
- Locations
- 🇬🇧
John Radcliffe Hospital, Oxford, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.